New details from the Phase 3 trial of the leading Lyme disease vaccine candidate, presented at the IDWeek infectious disease meeting in Washington, show that its efficacy of more than 70% was measured only after participants had received all four doses and entered a second tick season. One independent expert said that timing raises a practical question for families: how long they would wait before being protected.
The vaccine, PF-07307405 (LB6V, formerly VLA15), is being developed by Pfizer and Valneva and is not approved anywhere. The presentation added participant numbers and safety conclusions but did not change the core result: The trial narrowly missed its main statistical target.